此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

3%的diquafosol眼科溶液,用于主动中度至重度角膜结膜炎

2026年11月5日 更新者:The University of Hong Kong

3%Diquafosol眼科溶液的随机对照试验,用于主动中度至重度角膜结膜炎

The aim of the study is to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution in terms of symptoms and signs of VKC, tear film metrics, ocular surface inflammation and quality of life. Potential beneficial effect of Diquafosol treatment on top of current standard use of topical immunosuppressant therapy in VKC would be studied.

Subject at least aged 6 and above with clinical diagnosis of vernal keratoconjunctivitis would be invited to join this study and perform the following assessments:

  1. best corrected visual acuity,
  2. slit lamp biomicroscope examination,
  3. tear meniscus height and non-invasive keratographic tear breakup time(NIKBUT) measurement,
  4. cornea fluorescein staining (CFS) and
  5. Schirmer's I test. Doctor will prescribe eyedrop, 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion or 0.1% Cyclosporin A cationic ophthalmic emulsion at the end of examination. Subjects will be followed up at 4 weeks, 8 weeks, 16 weeks after treatment.

All participants will be required to answer a standardised questionnaire relating to severity of VKC and dry eye disease.

研究概览

详细说明

Aim To compare the four-month clinical efficacy of topical treatment with 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion versus 0.1% Cyclosporin A cationic ophthalmic emulsion in reducing symptoms and signs of active moderate-to-severe vernal keratoconjunctivitis (grade of 2 to 4 on the Bonini severity scale) with keratitis (corneal fluorescein staining score of 1-5 on the modified Oxford scale).

Study design A single-centre prospective double-blinded randomized controlled trial

Hypothesis The addition of topical treatment with 3% Diquafosol ophthalmic solution is superior to 0.1% Cyclosporin cationic ophthalmic emulsion alone in improving symptoms and signs of moderate-to-severe VKC with keratitis at four months of use.

Methods This is a single-centre, prospective, 16-week, randomized, double-blinded controlled clinical trial investigating the clinical efficacy and safety of combined topical treatment with 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion and versus topical treatment with 0.1% Cyclosporin A cationic ophthalmic emulsion in patients with moderate-to-severe vernal keratoconjunctivitis and keratitis. The study will also investigate the longitudinal changes in tear cytokines and correlate them with changes in VKC signs and tear film metrics. The study will be performed in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonization, Good Clinical Practice guidelines, and all applicable laws and regulations. Written informed consent will be obtained from each patient before enrolment in the study. A clinical trials certificate will be obtained from the Department of Health, Hong Kong SAR.

Sample size The study will recruit 94 subjects with moderate-to-severe VKC at eye clinics in Hong Kong West cluster (QMH and GH).

Sample size Calculation Sample size calculation is based on the findings from a prospective study comparing the combined use of 3% Diquafosol and 0.1% Cyclosporin versus 0.1% Cyclosporin alone in the treatment of dry eye disease in 279 subjects [36]. It is anticipated that a similar, if not larger, effective size in VKC patients compared to dry eye patients would be seen. In this study the mean change in cornea staining score between baseline and week 12 was significantly higher in Cyclosporin A and Diquafosol combination therapy (2.91 ± 3.93) than in Cyclosporin A monotherapy (0.93± 2.22). The estimated Cohen's d for this study is approximately 0.620. Based on calculations, approximately 41 participants per group to achieve a study power of 80% with a significance level of 0.05 and the estimated effect size of 0.620 is needed. Considering a 10% dropout rate, the adjusted sample size per group would be approximately 47 participants.

Randomization method Randomisation is conducted by computer-generated random number allocation and will be applied to sequentially enrolled participants. The randomisation schedule is pre-determined, prior to commencing participant recruitment, such that the investigator involved in baseline participant assessment will have no involvement in treatment allocation. Block randomization is performed to ensure 1:1 distribution into treatment groups.

Double-blinding To keep the investigators and subjects blind to the study treatment, all investigational drugs are removed from their commercial packaging, wrapped in aluminium foil, double-wrapped in plastic bags, and distributed to participants by an independent clinical research coordinator.

Rescue Therapy During the study period rescue medication (Loteprednolol 0.5% one drop 4x/day for up to 5 days) is permitted in the event of worsening of ocular surface symptoms. A maximum of 2 courses were allowed between study visits. Any use of rescue therapy is documented in the eyedrop diary and serves as one of the outcome measures.

Patient Workflow The patient workflow is aimed at obtaining clear and comprehensive documentation of symptoms and signs baseline and each subsequent visit after initiation of intervention. Furthermore, documentation of adverse events is achieved via assessment of best corrected visual acuity, intraocular pressure measurement, general periorbital area assessment and slit lamp biomicroscope assessment. See Figure 1. Study Workflow

In particular, the sequence of clinical assessments must be done in order of sequence from least invasive to most invasive, as any touching of the ocular surface or manipulation of the eyelids will stimulate tear secretion. Least invasive tests include imaging-based assessments without manipulation or touching of the ocular surface, include best corrected visual acuity, slit lamp biomicroscope assessment, NIKBUT and tear meniscus height. Mildly invasive tests include those that require gentle touching of the ocular surface, such as fluorescein cornea staining. Moderately invasive tests include those with prolonged ocular surface contact, such as the Schirmer's I test for tear collection

研究类型

介入性

注册 (估计的)

94

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Kendrick Co Shih
  • 电话号码:39621412
  • 邮箱:kcshih@hku.hk

学习地点

      • Hong Kong、香港
        • 招聘中
        • HKU Eye Centre
        • 接触:
          • Kendrick Co SHIH
          • 电话号码:94326271
          • 邮箱:kcshih@hku.hk

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Subject at least aged 6 and above
  • Clinical diagnosis of vernal keratoconjunctivitis
  • Evidence of active moderate-to-severe disease: At least Grade 2 on the Bonini scale of VKC clinical presentation (moderate-to-severe) [38].
  • Evidence of keratitis: At least Grade 1 on the Modified Oxford scale for cornea fluorescein staining as reported by Bron et al [39].
  • Experienced 1 or more recurrences of VKC during the previous year

Exclusion Criteria:

  • Nasolacrimal duct obstruction
  • Impaired blinking function
  • Active ocular infection or history of ocular herpes, varicella zoster or vaccinia virus infection
  • Any ocular disease that would require topical ocular treatment during the study
  • Use of cyclosporin A or tacrolimus eyedrops, or use of systemic immunosuppressants within 3 months before enrolment
  • Any ocular surgery within 6 months before enrolment

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion

3% Diquafosol eyedrops 6x/day + 0.1% Cyclosporin A twice a day

This arm is to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution

有源比较器:0.1% Cyclosporin A cationic ophthalmic emulsion

0.1% Cyclosporin A eyedrops twice a day + preservative free sodium hyaluronate eyedrops 6x/day

This arm is a control group to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Cornea Fluorescein Staining (CFS) score from baseline to 4 weeks, 8 weeks and 16 weeks between study groups
大体时间:From baseline to 4 months post- treatment between study groups

Higher values mean inferior outcomes. Graded according to the modified Oxford grading scale (range 0, 0.5, 1, 2, 3, 4, 5). A difference in score of at least 2 levels (i.e. 4 to 2) or complete resolution of staining (i.e. 0) are both considered clinically significant endpoints.

From baseline to 4 months post- treatment between study groups

次要结果测量

结果测量
措施说明
大体时间
Percentage of patients requiring rescue topical steroid therapy at 4 weeks, 8 weeks and 16 weeks
大体时间:From baseline to 4 months post- treatment between study groups

Number of patients requiring rescue topical steroid therapy divided by all patients participated in this study

From baseline to 4 months post- treatment between study groups
Percentage of patients with improvement in Cornea Fluorescein Staining (CSF) at 4 weeks, 8 weeks and 16 weeks
大体时间:From baseline to 4 months post- treatment between study groups

Number of patients with improvement in CFS requiring rescue topical steroid therapy divided by all patients participated in this study

From baseline to 4 months post- treatment between study groups
Change in best corrected visual acuity from baseline to 4 weeks, 8 weeks and 16 weeks
大体时间:From baseline to 4 months post- treatment between study groups

From logmar(1.0 to -0.1)

From baseline to 4 months post- treatment between study groups
Change in Standard Patient Evaluation of Eye Dryness Questionnaire (SPEED) score from baseline to 4 weeks, 8 weeks and 16 weeks
大体时间:From baseline to 4 months post- treatment between study groups

Range from 0-28, one mark was collected per patient, with higher scores meaning worse

From baseline to 4 months post- treatment between study groups
Change in Quality of Life in Children with Vernal Keratoconjunctivitis (QUICK) score from baseline to 4 weeks, 8 weeks and 16 weeks
大体时间:From baseline to 4 months post- treatment between study groups

Range from 0-48, one mark was collected per patient, with higher scores meaning worse outcomes

From baseline to 4 months post- treatment between study groups
Change in NIKBUT from baseline to 4 weeks, 8 weeks and 16 weeks
大体时间:From baseline to 4 months post- treatment between study groups

NIKBUT is measured in seconds and average of 3 consecutive readings is taken. Higher values mean better outcomes.

From baseline to 4 months post- treatment between study groups
Change in tear meniscus height from baseline to 4 weeks, 8 weeks and 16 weeks
大体时间:From baseline to 4 months post- treatment between study groups

In millimetres. Readings serve as objective parameters for tear volume

From baseline to 4 months post- treatment between study groups
Change in tear cytokines from baseline to 4 weeks, 8 weeks and 16 weeks
大体时间:From baseline to 4 months post- treatment between study groups

Percentage change in tear cytokines analysis done in lab

From baseline to 4 months post- treatment between study groups

其他结果措施

结果测量
措施说明
大体时间
Incidence of ocular adverse events
大体时间:From baseline to 4 months post- treatment between study groups

Number of patients with ocular adverse events divided by all patients participated in this study

From baseline to 4 months post- treatment between study groups
Incidence of non-ocular adverse events
大体时间:From baseline to 4 months post- treatment between study groups

Number of patients with non-ocular adverse events divided by all patients participated in this study

From baseline to 4 months post- treatment between study groups
• Incremental cost-effectiveness ratio (ICER) in cost per quality-adjusted life year (QALYs) gained.
大体时间:From baseline to 4 months post- treatment between study groups

It is defined by the difference in cost between two possible interventions, divided by the difference in their effect.

From baseline to 4 months post- treatment between study groups

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Kendrick Co Shih、The University of Hong Kong, Grantham Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年2月9日

初级完成 (估计的)

2028年6月30日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2025年3月25日

首先提交符合 QC 标准的

2025年3月25日

首次发布 (实际的)

2025年4月1日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅